Contact
321 Avenue Jean Jaurès
69007 Lyon
France
CEO & Co-fondateur
About us
NETRI, industrial start-up, develops organs-on-chip technologies which, coupled with AI treatments, enable the prediction of a drug candidate's or products's clinical effect. NETRI offers its customers support throughout the development of their drug or product candidate by providing predictive answers on toxicity, efficacy and modes of action in the discovery, preclinical and clinical phases. Organs-on-chip devices enable the creation of healthy or pathological physiological models. Using its high-throughput microfluidic technologies, NETRI's models recreate human physiology in vitro by co-culturing cells, either primary or derived from human stem cells, compartmentalized and coupled with functional activity measurements. NETRI today markets its NeuroFludidics™ organs-on-chip models in pain, dermo-cosmetics and nutritional health applications.
Business offer
From discovery to clinical phase, NETRI offers high-throughput organ-on-chip devices, drug screening services, functional data analysis services through access to our AI algorithm and co-development services. NETRI's organ-on-chip technologies enable different organs to be innervated, vascularized and interconnected using human stem cells. By recording the activity of neurons, used as a natural biosensor of a biological effect, innervating these organs, our solutions enable us to predict the clinical toxicological and efficacy responses of drug candidates or products using our AI algorithm previously trained on the results of clinical studies of our customers' drug candidates or products.
Activities
- Service
- Technology Supplier
- Oncology
- Nervous Central System
- Immunology
- Ophthalmology
- Inflammation
